-
1
-
-
0003397692
-
-
Accessed June 16, 2014
-
American Cancer Society. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed June 16, 2014.
-
Cancer Facts & Figures 2014
-
-
-
2
-
-
0041330535
-
Yondelis (trabectedin, ET-743): The development of an anticancer agent of marine origin
-
C. van Kesteren, M.M. de Vooght, and L. Lopez-Lazaro Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin Anticancer Drugs 14 2003 487 502
-
(2003)
Anticancer Drugs
, vol.14
, pp. 487-502
-
-
Van Kesteren, C.1
De Vooght, M.M.2
Lopez-Lazaro, L.3
-
3
-
-
0032542724
-
Mechanism for the catalytic activation of ecteinasacidin 743 and its subsequent alkylation of guanine N2
-
B.M. Moore, F.C. Seaman, and R.T. Wheelhouse Mechanism for the catalytic activation of ecteinasacidin 743 and its subsequent alkylation of guanine N2 J Am Chem Soc 120 1998 2490 2491
-
(1998)
J Am Chem Soc
, vol.120
, pp. 2490-2491
-
-
Moore, B.M.1
Seaman, F.C.2
Wheelhouse, R.T.3
-
4
-
-
0033566150
-
Ecteinascidin-743: A minor groove alkylator that bends DNA towards the major groove
-
M. Zewail-Foote, and L.H. Hurley Ecteinascidin-743: a minor groove alkylator that bends DNA towards the major groove J Med Chem 42 1999 2493 2497
-
(1999)
J Med Chem
, vol.42
, pp. 2493-2497
-
-
Zewail-Foote, M.1
Hurley, L.H.2
-
5
-
-
0029838307
-
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
-
Y. Pommier, G. Kohlhagen, and C. Bailly DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata Biochemistry 35 1996 13303 13309
-
(1996)
Biochemistry
, vol.35
, pp. 13303-13309
-
-
Pommier, Y.1
Kohlhagen, G.2
Bailly, C.3
-
6
-
-
0035146702
-
Ecteinascidin-743 (ET-743), a natural marine compound with a unique mechanism of action
-
E. Erba, D. Bergamaschi, and L. Bassano Ecteinascidin-743 (ET-743), a natural marine compound with a unique mechanism of action Eur J Cancer 37 2001 97 105
-
(2001)
Eur J Cancer
, vol.37
, pp. 97-105
-
-
Erba, E.1
Bergamaschi, D.2
Bassano, L.3
-
7
-
-
0035542848
-
Antitumor activity- and gene expression-based profiling of ecteinascidin ET-743 and phthalascidin Pt 650
-
E.J. Martinez, E.J. Corey, and T. Owa Antitumor activity- and gene expression-based profiling of ecteinascidin ET-743 and phthalascidin Pt 650 Chem Biol 8 2001 1151 1160
-
(2001)
Chem Biol
, vol.8
, pp. 1151-1160
-
-
Martinez, E.J.1
Corey, E.J.2
Owa, T.3
-
8
-
-
0037096739
-
Ecteinascidin-743 inhibits activated but not constitutive transcription
-
D. Friedman, Z. Hu, and E.A. Kolb Ecteinascidin-743 inhibits activated but not constitutive transcription Cancer Res 62 2002 3377 3381
-
(2002)
Cancer Res
, vol.62
, pp. 3377-3381
-
-
Friedman, D.1
Hu, Z.2
Kolb, E.A.3
-
9
-
-
17944374027
-
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
-
Y. Takebayashi, P. Pouquier, and D.B. Zimonjic Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 2001 961 966
-
(2001)
Nat Med
, vol.7
, pp. 961-966
-
-
Takebayashi, Y.1
Pouquier, P.2
Zimonjic, D.B.3
-
10
-
-
0035874074
-
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
-
G. Damia, S. Silvestri, and L. Carrassa Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways Int J Cancer 92 2001 583 588
-
(2001)
Int J Cancer
, vol.92
, pp. 583-588
-
-
Damia, G.1
Silvestri, S.2
Carrassa, L.3
-
11
-
-
0242559104
-
Preclinical and clinical results with the natural marine product ET-743
-
M. D'Incalci, and J. Jimeno Preclinical and clinical results with the natural marine product ET-743 Expert Opin Investig Drugs 12 2003 1 11
-
(2003)
Expert Opin Investig Drugs
, vol.12
, pp. 1-11
-
-
D'Incalci, M.1
Jimeno, J.2
-
12
-
-
0032693607
-
High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
-
H.R. Hendriks, H.H. Fiebig, and R. Giavazzi High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer Ann Oncol 10 1999 1233 1240
-
(1999)
Ann Oncol
, vol.10
, pp. 1233-1240
-
-
Hendriks, H.R.1
Fiebig, H.H.2
Giavazzi, R.3
-
13
-
-
0031766324
-
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
-
E. Izbicka, R. Lawrence, and E. Raymond In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients Ann Oncol 9 1998 981 987
-
(1998)
Ann Oncol
, vol.9
, pp. 981-987
-
-
Izbicka, E.1
Lawrence, R.2
Raymond, E.3
-
14
-
-
0034813203
-
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent
-
W.W. Li, N. Takahashi, and S. Jhanwar Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent Clin Cancer Res 7 2001 2908 2911
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2908-2911
-
-
Li, W.W.1
Takahashi, N.2
Jhanwar, S.3
-
15
-
-
0036895987
-
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells
-
K. Scotlandi, S. Perdichizzi, and M.C. Manara Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells Clin Cancer Res 8 2002 3893 3903
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3893-3903
-
-
Scotlandi, K.1
Perdichizzi, S.2
Manara, M.C.3
-
16
-
-
0038380364
-
Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743
-
A. Kanzaki, Y. Takebayashi, and X.Q. Ren Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743 Mol Cancer Ther 1 2002 1327 1334
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 1327-1334
-
-
Kanzaki, A.1
Takebayashi, Y.2
Ren, X.Q.3
-
17
-
-
0344570127
-
Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines ()
-
( 3896)
-
H. Barrera, R. Moore, and J. Jimeno Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines () Proc Am Assoc Cancer Res 40 1999 591 ( 3896)
-
(1999)
Proc Am Assoc Cancer Res
, vol.40
, pp. 591
-
-
Barrera, H.1
Moore, R.2
Jimeno, J.3
-
18
-
-
0035281641
-
Phase i and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
-
A. Taamma, J.L. Misset, and M. Riofrio Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors J Clin Oncol 19 2001 1256 1265
-
(2001)
J Clin Oncol
, vol.19
, pp. 1256-1265
-
-
Taamma, A.1
Misset, J.L.2
Riofrio, M.3
-
19
-
-
33745259879
-
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
-
L. Zelek, A. Yovine, and E. Brain A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer Br J Cancer 94 2006 1610 1614
-
(2006)
Br J Cancer
, vol.94
, pp. 1610-1614
-
-
Zelek, L.1
Yovine, A.2
Brain, E.3
-
20
-
-
0142121506
-
Phase i and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
-
C. Twelves, K. Hoekman, and A. Bowman Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours Eur J Cancer 39 2003 1842 1851
-
(2003)
Eur J Cancer
, vol.39
, pp. 1842-1851
-
-
Twelves, C.1
Hoekman, K.2
Bowman, A.3
-
21
-
-
0141731283
-
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat
-
S. Donald, R.D. Verschoyle, and P. Greaves Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat Cancer Res 63 2003 5902 5908
-
(2003)
Cancer Res
, vol.63
, pp. 5902-5908
-
-
Donald, S.1
Verschoyle, R.D.2
Greaves, P.3
-
22
-
-
0036387382
-
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity
-
T.A. Puchalski, D.P. Ryan, and R. Garcia-Carbonero Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity Cancer Chemother Pharmacol 50 2002 309 319
-
(2002)
Cancer Chemother Pharmacol
, vol.50
, pp. 309-319
-
-
Puchalski, T.A.1
Ryan, D.P.2
Garcia-Carbonero, R.3
-
23
-
-
42149132719
-
Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
-
G.J. Fetterly, J.S. Owen, and K. Stuyckens Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment Cancer Chemother Pharmacol 62 2008 135 147
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 135-147
-
-
Fetterly, G.J.1
Owen, J.S.2
Stuyckens, K.3
-
24
-
-
33745161449
-
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
-
F. Grosso, P. Dileo, and R. Sanfilippo Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma Eur J Cancer 42 2006 1484 1490
-
(2006)
Eur J Cancer
, vol.42
, pp. 1484-1490
-
-
Grosso, F.1
Dileo, P.2
Sanfilippo, R.3
-
25
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
26
-
-
0027965381
-
Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer
-
K. Porkka, C. Blomqvist, and P. Rissanen Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer J Clin Oncol 12 1994 1639 1647
-
(1994)
J Clin Oncol
, vol.12
, pp. 1639-1647
-
-
Porkka, K.1
Blomqvist, C.2
Rissanen, P.3
-
27
-
-
67549088920
-
Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide ()
-
( 10060)
-
J.A. Morgan, A. Le Cesne, and S. Chawla Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide () J Clin Oncol 25 2007 559s ( 10060)
-
(2007)
J Clin Oncol
, vol.25
, pp. 559s
-
-
Morgan, J.A.1
Le Cesne, A.2
Chawla, S.3
-
28
-
-
37049010261
-
Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies ()
-
( 5579)
-
S. McMeekin, J.M. del Campo, and N. Colombo Trabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis of three phase II studies () J Clin Oncol 25 2007 293s ( 5579)
-
(2007)
J Clin Oncol
, vol.25
, pp. 293s
-
-
McMeekin, S.1
Del Campo, J.M.2
Colombo, N.3
-
29
-
-
0035281734
-
Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity
-
S. Delaloge, A. Yovine, and A. Taamma Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity J Clin Oncol 19 2001 1248 1255
-
(2001)
J Clin Oncol
, vol.19
, pp. 1248-1255
-
-
Delaloge, S.1
Yovine, A.2
Taamma, A.3
-
30
-
-
20044372153
-
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
-
A. Le Cesne, J.Y. Blay, and I. Judson Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial J Clin Oncol 23 2005 576 584
-
(2005)
J Clin Oncol
, vol.23
, pp. 576-584
-
-
Le Cesne, A.1
Blay, J.Y.2
Judson, I.3
-
31
-
-
24944460785
-
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
-
R. Garcia-Carbonera, J.G. Supko, and J. Maki Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 2005 5484 5492
-
(2005)
J Clin Oncol
, vol.23
, pp. 5484-5492
-
-
Garcia-Carbonera, R.1
Supko, J.G.2
Maki, J.3
-
32
-
-
2342461682
-
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
-
R. Garcia-Carbonero, J.G. Supko, and J. Manola Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol 22 2004 1480 1490
-
(2004)
J Clin Oncol
, vol.22
, pp. 1480-1490
-
-
Garcia-Carbonero, R.1
Supko, J.G.2
Manola, J.3
-
33
-
-
1542398698
-
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
-
A. Yovine, M. Riofrio, and J.Y. Blay Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients J Clin Oncol 22 2004 890 899
-
(2004)
J Clin Oncol
, vol.22
, pp. 890-899
-
-
Yovine, A.1
Riofrio, M.2
Blay, J.Y.3
-
34
-
-
0036270843
-
ET-743: The US experience in sarcomas of soft tissues
-
G.D. Demetri ET-743: the US experience in sarcomas of soft tissues Anticancer Drugs 13 suppl 1 2002 S7 9
-
(2002)
Anticancer Drugs
, vol.13
, pp. 7-9
-
-
Demetri, G.D.1
-
35
-
-
20144377216
-
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
-
C. Sessa, F. De Braud, and A. Perotti Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails J Clin Oncol 23 2005 1867 1874
-
(2005)
J Clin Oncol
, vol.23
, pp. 1867-1874
-
-
Sessa, C.1
De Braud, F.2
Perotti, A.3
-
36
-
-
37049038819
-
A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
-
C.N. Krasner, D.S. McMeekin, and S. Chan A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 2007 1618 1624
-
(2007)
Br J Cancer
, vol.97
, pp. 1618-1624
-
-
Krasner, C.N.1
McMeekin, D.S.2
Chan, S.3
-
37
-
-
84882449972
-
Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study
-
G. Ferrandina, V. Salutari, and B. Vincenzi Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study Gynecol Oncol 130 2013 505 510
-
(2013)
Gynecol Oncol
, vol.130
, pp. 505-510
-
-
Ferrandina, G.1
Salutari, V.2
Vincenzi, B.3
-
38
-
-
47549083451
-
DNA repair functionality as a molecular signature for sensitivity(S)/resistance(R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis) ()
-
Accessed February 1, 2012
-
Schoffski P, Grosso F, Taron M, et al. DNA repair functionality as a molecular signature for sensitivity(S)/resistance(R) in sarcoma patients (pts) treated with trabectedin (ET-743, Yondelis) (). Annual Meeting of the American Association for Cancer Research (AACR) Meeting s 2007 ( 144). Available at: http://www.aacrmeetings.org/cgi/content/meeting-/2007/1-Annual-Meeting/144. Accessed February 1, 2012.
-
(2007)
Annual Meeting of the American Association for Cancer Research (AACR) Meetings
, Issue.144
-
-
Schoffski, P.1
Grosso, F.2
Taron, M.3
-
39
-
-
84910655313
-
Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients
-
Accessed September 2, 2014
-
Rosell R, Martinez N, Rodriguez S, et al. Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients (). Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2007 ( C127). Available at: http://www.aacrmeetings.org/cgi/gca?allch=&SEARCHID=1&AUTHOR1=Rosell&FULLTEXT=XPG&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca=aacrmtg%3B2007%2F3-Molecular-Targets-Meeting%2FC127. Accessed September 2, 2014.
-
(2007)
Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
, pp. C127
-
-
Rosell, R.1
Martinez, N.2
Rodriguez, S.3
-
40
-
-
77955491837
-
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
-
B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
-
(2010)
J Clin Oncol
, vol.28
, pp. 3107-3114
-
-
Monk, B.J.1
Herzog, T.J.2
Kaye, S.B.3
|